LIVER FUNCTION TESTS REIMAGINED: EMERGING BIOMARKERS, NON-INVASIVE DIAGNOSTIC ALGORITHMS, AND THE 2023–2025 GUIDELINE REVOLUTION

Authors

  • Naveen Prabakaran C Associate Professor of Biochemistry, Department of International Studies, Asia International University, Bukhara, Uzbekistan Author

Keywords:

liver function tests; non-invasive fibrosis markers; MASLD; Enhanced Liver Fibrosis test; MELD 3.0; clinical guidelines

Abstract

Liver function tests (LFTs) remain the most frequently ordered laboratory panel in clinical medicine, yet conventional aminotransferase-based testing has limited sensitivity for early fibrosis and often misclassifies clinically significant disease. Between 2023 and 2025, hepatology practice underwent substantial revision: fatty liver disease was renamed under the steatotic liver disease (SLD) framework, non-invasive fibrosis algorithms combining indirect indices with direct biomarkers were formally endorsed, imaging-based thresholds were codified, and transplant-allocation scoring was refined through MELD 3.0. This article reviews newer test protocols including the Enhanced Liver Fibrosis (ELF) test, vibration-controlled transient elastography with controlled attenuation parameter (CAP), the GALAD score, and algorithm-driven reflex pathways such as intelligent Liver Function Testing (iLFT) alongside the 2023–2025 AASLD and EASL–EASD–EASO guideline updates, to provide a concise, exam-oriented synthesis for clinicians and students.

References

1.Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, et al. Guidelines on the management of abnormal liver blood tests. Gut. 2018;67(1):6–19.

2.Kwo PY, Cohen SM, Lim JK. ACG clinical guideline: evaluation of abnormal liver chemistries. Am J Gastroenterol. 2017;112(1):18–35.

3.Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542–56.

4.Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–1835.

5.European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL–EASD–EASO clinical practice guidelines on the management of metabolic dysfunction associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492–542.

6.Chen VL, Morgan TR, Rotman Y, Kleiner DE, Van Natta ML, Sanyal AJ, et al. Resmetirom therapy for metabolic dysfunction associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance. Hepatology. 2024 Oct 18. Epub ahead of print.

7.Sterling RK, Duarte-Rojo A, Patel K, Asrani SK, Alsawas M, Dranoff JA, et al. AASLD Practice Guideline on imaging based noninvasive liver disease assessment of hepatic fibrosis and steatosis. Hepatology. 2025;81(2):672–724.

8.European Association for the Study of the Liver. EASL Clinical Practice Guidelines on non invasive tests for evaluation of liver disease severity and prognosis—2021 update. J Hepatol. 2021;75(3):659–89.

9.Sharma C, Cococcia S, Ellis N, Parkes J, Rosenberg W. Systematic review: accuracy of the enhanced liver fibrosis test for diagnosing advanced liver fibrosis and cirrhosis. J Gastroenterol Hepatol. 2021;36(7):1788–802.

10.Kjaergaard M, Lindvig KP, Thorhauge KH, Andersen P, Hansen JK, Kastrup N, et al. Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. J Hepatol. 2023;79(2):277–86.

11.Nobes J, Leith D, Handjiev S, Dillon JF, Dow E. Intelligent Liver Function Testing (iLFT): an intelligent laboratory approach to identifying chronic liver disease. Diagnostics (Basel). 2024;14(9):960.

12.Johnson PJ, Pirrie SJ, Cox TF, Berhane S, Teng M, Palmer D, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev. 2014;23(1):144–53.

13.Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464–70.

14.Kim WR, Mannalithara A, Heimbach JK, Kamath PS, Asrani SK, Biggins SW, et al. MELD 3.0: the Model for End-Stage Liver Disease updated for the modern era. Gastroenterology. 2021;161(6):1887–95.

15.Mazumder NR, Fontana RJ. MELD 3.0 in advanced chronic liver disease. Annu Rev Med. 2024;75:233–45.

Downloads

Published

2026-07-17